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MechanismABSTRACT
Objective: To discuss the effect of dimethyl fumarate (DMF) on rats with L-arginine
induced chronic pancreatitis (CP).
Methods: Male Wistar rats were given DMF treatment (25 mg/kg) by oral lavage
method; then Wistar rats were given the intraperitoneal injection of L-arginine for 5 times
(250 mg/100 kg, twice per time, each interval of 1 h) for building of CP model. Rats were
divided into control group, CP group, DMF group and CP + DMF group. Rats in
CP + DMF group were given the oral intragastric administration of DMF (25 mg/kg),
while rats in control group and CP group were given the equal volume of normal saline.
The weight of rats was evaluated and the intraperitoneal glucose tolerance test was
performed (IPGTT, 2 g/kg). The islet of rats was isolated and then ﬂow cytometry was
employed to evaluate the quality and activity of islets. Meanwhile, the histology of non-
endocrine tissues and levels of myeloperoxidase (MPO) and malondialdehyde (MDA)
were detected.
Results: Compared with control group, the weight of rats in CP group was signiﬁcantly
reduced at week 2, 4 and 6; the blood glucose signiﬁcantly increased, AUC increased, the
histopathological scores of pancreatic atrophy, acinar injury, edema and cellular inﬁl-
tration increased, levels of MDA and MPO increased, the islet equivalent and islet ac-
tivity decreased at 0, 30, 60, 120 and 180 min. Compared with CP group, the weight of
rats in CP + DMF group signiﬁcantly increased at week 2, 4 and 6; the blood glucose
signiﬁcantly decreased, AUC decreased, the histopathological scores of pancreatic atro-
phy, acinar injury, edema and cellular inﬁltration decreased, levels of MDA and MPO
decreased, the islet equivalent and islet activity increased at 0, 30, 60, 120 and 180 min.
Conclusions: DMF treatment can improve CP induced by L-arginine and islet function in
rats.1. Introduction
Chronic pancreatitis (CP) is a kind of progressive inﬂam-
matory diseases, which would cause the damage and ﬁbrosis of
pancreas parenchyma and eventually lead to endocrine and
exocrine function obstacle [1–3]. Statistics indicated that CP
incidence was still increasing [4]. In a structured questionnaire,
CP patients indicated CP disease had the severe impact on
their body, social and psychological health [5]. At present, themain therapeutic method for CP is supportive care, including
nutrition and pain control [6,7]. But the speciﬁc pathogenesis
has not been clear and thus the clinical effect of main
treatments was poor [8,9].
Dimethyl fumarate (DMF) is used in the treatment of pa-
tients with multiple sclerosis [10,11]. The mechanism for DMF
has not been clear yet. However, its unique antioxidative and
anti-inﬂammatory features have already been proved [12–14].
CP could induce the oxidative stress and inﬂammation
response in islet endocrine and non-endocrine cells. Thus in
this study, it's presumed that DMF might inhibit the develop-
ment of CP through the antioxidant and anti-inﬂammatory
response. By building the rat model of CP and feeding rats
with the certain dose of DMF, it is to discuss the inhibition and
mechanism of DMF on the inﬂammation and oxidative stress of
rats with CP.BY-NC-ND license
Table 1
Weight changes in each group (g).
Group Week 2 Week 4 Week 6
Control group 110.45 ± 10.78 167.42 ± 15.63 198.42 ± 15.63
CP group 105.39 ± 10.20* 132.37 ± 13.24** 167.37 ± 15.38**
CP + DMF
group
108.42 ± 10.17# 158.48 ± 16.13## 188.52 ± 18.29##
Compared with control group, *P < 0.05, #P < 0.01; compared with CP
group, **P < 0.05, ##P < 0.01.
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2.1. Materials
2.1.1. Animals
Male Wistar rats (250–300 g) were purchased from Hebei
University of Engineering laboratory, and all rats were raised in
a sterile environment at (22 ± 2) C, free access to eating and
drinking, with fasting for 12 h before experiment.
2.1.2. Reagents
L-arginine and DMF were purchased from Sigma; HE,
TMRE and 7-AAD dye from Sigma; malondialdehyde (MDA)
kit and myeloperoxidase (MPO) kit from Nanjing Jiansheng
Biological Products Research Institute; collagenaseV from
Sigma; dithizone (DTZ) from Shanghai No.3 Reagent Factory;
rabbit-derived polyclonal insulin and glucagonantibody from
Santa.
2.2. Methods
2.2.1. Building of CP model
L-arginine was dissolved in NS (20%), with the intraperito-
neal injection of L-arginine (250 mg/100 kg, twice per time,
every interval of 1 h) for 5 times (day 1, 5, 9, 13 and 17); after 7
weeks, rats were put to death. Feom 24 h before building of CP
model, rats were given DMF treatment (25 mg/kg) by oral
lavage method. Rats in the control group and CP group were
given the equal volume of normal saline. After 7 weeks of
administration, rats were put to death.
2.2.2. Intraperitoneal glucose tolerance (GT) test
(IPGTT)
At week 7 of modeling, the intragastric administration of 2 g/
kg glucose was performed and the blood was collected from the
caudal vein. The trace glucose meter was employed to detect the
blood glucose of rats at fasting, 30, 60, 90, 120 and 180 min
after dining, as well as the area under the curve (AUC),
AUC = 1/2 fasting value + value at 1 h + value at 2 h + 1/2 value
at 3 h.
2.2.3. Histological analysis
After 7 weeks, rats were put to death. Then the pancreas of
rats was taken out for stabilization and the biochemical analysis
was performed. Firstly, pancreas was ﬁxed with 10% of
formalin, embedded with parafﬁn, sliced into 5 mm pieces and
then HE staining was conducted. Schmidt standard was adopted
to evaluate the histological analysis based on the area of lesions,
alveolus atrophy, acinar cell damage, ﬁbrosis, interstitial edema
and inﬂammatory cell inﬁltration.
2.2.4. Pancreas MDA and MPO detection
The partial pancreatic tissues of rats were collected for
weighing. After that, the equivalent NS was added and l% of
homogenate (made from low temperature homogenate machine)
was used for being centrifuged at room temperature (3000 g/
min, 10 min) to obtain the supernatant. Finally, MDA content
was detected according to the procedure of MDA kit. The extra
partial pancreatic tissues of rats were collected for weighing.
After that, the equivalent NS was added and l% of homogenate
(made from low temperature homogenate machine) was used forbeing centrifuged at room temperature (3000 g/min, 10 min) to
obtain the supernatant. Finally, MDA content was detected using
the chemoenzymatic method. Operations should be strictly in
accordance with the instruction manual.
2.2.5. Islet isolation and endocrine function evaluation
After taking out of the pancreas and weighing, common bile
duct puncture and injection of cold collagen V (10 mL) digestive
juices were conducted, which could make the pancreas adequate
swelling. Afterwards, pancreas was put into cold collagen V
(5 mL) digestive juices and digested in 37 C water bath for
10 min; then Hanks solution (contained 10% of fetal calf serum)
was used for digestion termination, mesh screen ﬁltration, cen-
trifugal collecting of the islet. 50 mL of DTZ working solution
was mixed with 50 mL of islet for 5 min. The cell mass numbers
of scarlet DTZ staining was counted under the microscope,
which was equivalent to the (150 mm in diameter) islet equiv-
alent quantity according to formula conversion and then the total
obtained islet equivalent quantity was calculated.
2.2.6. Islet activity evaluation
Cultured islet was separated into single-cell suspension
liquid. Cells were placed into ﬂow cytometry instrument for
TMRE staining after being washed. TMRE was selectively
combined with mitochondrial membrane to detect the cell
apoptosis. After being washed, cell 7-AAD was stained. 7-AAD
combined with cell DNA indicated the cell membrane perme-
ability changes after cell death.
2.2.7. Islet alpha/beta cell ratio
Single-cell suspension liquid was placed in 4% of para-
formaldehyde and was ﬁxed for 10 min at room temperature.
After continuous PBS washing, cell was incubated by polyclonal
insulin in rabbit and anti-Glucagon. Afterwards, the goat-anti-
rabbit secondary antibody was used for marking and the ﬂow
cytometry (FCM) was employed for the analysis.
2.2.8. Statistical analysis
Data was expressed by mean ± sd. The t test or one-way
analysis of variance was employed for the comparison be-
tween groups, where P < 0.05 indicated the statistical difference.
3. Results
3.1. Effect of DMF on weight of rats with CP
As shown in Table 1, as the time of modeling passed, the
weight of rats in control group, CP group and CP + DMF group
signiﬁcantly increased, but the weight of rats in CP group was
signiﬁcantly lower than that in control group at week 2, with the
Table 2
IPGTT results in each group (mmol/L).
Group 0 min 30 min 60 min 120 min 180 min
Control group 4.05 ± 0.40 6.72 ± 0.66 6.34 ± 0.62 5.26 ± 0.53 4.16 ± 0.42
CP group 5.73 ± 0.52** 8.96 ± 0.90** 9.03 ± 0.92** 7.28 ± 0.75** 6.57 ± 0.66**
CP + DMF group 4.89 ± 0.50## 7.31 ± 0.73## 7.04 ± 0.70## 6.11 ± 0.60## 4.86 ± 0.49##
Compared with the control group, #P < 0.01; compared with CP group, ##P < 0.01.
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signiﬁcantly higher than that in CP group, with the statistical
difference (P < 0.05). The same situation was found at week 4
and 6. It indicated that, as the time of modeling passes, the
weight of CP rats increased slowly, which was lower than that in
the normal group. After being given GMF, the weight of CP rats
was recovered gradually.
3.2. Improvement of DMF for GT in rats with CP
The results showed that the blood glucose level in CP group
was signiﬁcantly higher than that in the model group; while the
blood glucose level in CP + DMF group was signiﬁcantly lower
than that in CP group, with the statistical difference (P < 0.01).
Meanwhile, the same situation was found at 30 and 60 min. But
at 120 and 180 min, the blood glucose level in control group, CP
group and CP + DMF group was decreased a bit, but the one in
CP group was still signiﬁcantly higher than that in the model
group and the one in CP + DMF group was signiﬁcantly lower
than that in CP group, with the statistical difference (P < 0.01)
(Table 2).
The results showed that AUC value in CP group (22.46 ±
2.50) mmol/L$h−1 was signiﬁcantly higher than that in the control
group, (15.70 ± 1.45) mmol/L$h−1; while the one in CP + DMF
group, (18.02 ± 1.82) mmol/L$h−1 was signiﬁcantly lower than
that in CP group, with the statistical difference (P < 0.01).
3.3. Improvement of DMF for histopathology in rats
with CP
L-arginine could cause pancreatic histologic changes in rats,
including serious pancreatic acinar structure damages, edema
and fatty inﬁltration. Oral administration of DMF treatmentTable 3
Histopathological score of rats in each group.
Group Area of lesions Acinar cell damage
Control 0.00 ± 0.00 0.00 ± 0.00 0.
DMF 2.10 ± 0.20** 2.90 ± 0.30** 1.
CP + DMF 0.80 ± 0.10## 1.40 ± 0.20## 0.
Compared with the control group, #P < 0.01; compared with CP group, ##P
Table 4
Levels of MPO and MDA and islet equivalent and islet activity of rats in ea
Group MPO (U/mg protein) MDA (mmol/m
Control group 0.70 ± 0.05 0.24 ± 0.0
CP group 1.32 ± 0.14** 1.08 ± 0.1
CP + DMF group 0.89 ± 0.09## 0.54 ± 0.0
Compared with the control group, #P < 0.01; compared with CP group, ##Pcould signiﬁcantly improve the above symptoms. As shown in
Table 3, the histopathological score of the area of lesions, acinar
cell damage, edema and inﬂammatory cell inﬁltration in CP
group was signiﬁcantly higher than that in the control group;
while the histopathological score in CP + DMF group was
signiﬁcantly lower than that in CP group, with the statistical
difference (P < 0.01).
3.4. Improvement of DMF for biochemical parameter in
rats with CP
Compared with the control group, the levels of MPO and
MDA in CP group signiﬁcantly increased. After the treatment
of DMF, the levels of MPO and MDA in CP group signiﬁ-
cantly decreased. The islet equivalent and islet activity in CP
group were signiﬁcantly lower than those in the control group;
while the islet equivalent and islet activity in CP + DMF
group were signiﬁcantly higher than those in CP group
(Table 4).
4. Discussion
The results indicated the obvious difference of pathology,
histology and pancreas biochemical markers between CP + DMF
group and CP group. The weight of rats in CP + DMF group and
CP group at week 2, 4 and 6 was signiﬁcantly higher than that in
CP group; while the blood glucose level at 0, 30, 60, 120 and
180 min was signiﬁcantly lower than that in CP group and the
histopathological score of the area of lesions, acinar cell damage,
edema and inﬂammatory cell inﬁltration was signiﬁcantly lower
than that in CP group, which indicated that DMF could signiﬁ-
cantly improve the pathological changes of pancreas, the blood
glucose level and weight of CP rats. The results of comparison inEdema Fibrosis Inﬂammatory cell inﬁltration
20 ± 0.02 0.00 ± 0.00 0.00 ± 0.00
30 ± 0.20** 0.50 ± 0.30 2.70 ± 0.30**
90 ± 0.10## 0.50 ± 0.40 1.00 ± 0.10##
< 0.01.
ch group.
g protein) Islet equivalent (IEQ/g) Islet activity (%)
2 2873.5 ± 290.4 80.30 ± 8.60
0** 2451.4 ± 243.5** 49.60 ± 5.10**
5## 2732.8 ± 275.3## 74.50 ± 7.30##
< 0.01.
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showed no signiﬁcant difference, but it showed the certain ten-
dency of damage. Besides, DMF could also improve the ﬁbrosis
of pancreas of L-arginine induced CP rats. The ﬂow cytometry
was employed to evaluate the quality and activity of islets. The
results also indicated that DMF had the obvious protection for the
islet of L-arginine induced CP rats.
DMF had unique antioxidative and anti-inﬂammatory feature.
Although mechanism of DMF was not clear, its side-effect was
smaller, which made its use for more than 20 years. Fumarate was
mainly used in the treatment of psoriasis, which was based on its
inhibition of lymphocyte proliferation. Recent reports found that
DMF selectively increased Th2 cytokines and inhibited Th1 re-
sponses [15]. There were also researches showing that DMF
decreased the gene expression of pro-inﬂammatory cytokines
and chemotactic factors, and increased the expression of
antioxidant molecules [16–18]. These ﬁndings suggested that
DMF could be used in the treatment of autoimmune and
inﬂammatory diseases, including multiple sclerosis. Other
scholars reported that DMF played its antioxygenation role
through Nrf2 activator [14,15]. DMF was likely to have multiple
effective anti-oxidation mechanisms.
MPO is the marker of inﬂammatory stress, while MDA is the
by-product of lipid peroxidation, as the marker of cell injury and
oxidative stress. The results of this study indicated that the levels
of MPO and MDA were signiﬁcantly increased in CP group.
After the treatment of DMF for CP rats, the levels of MDA and
MPO signiﬁcantly decreased, which indicated that DMF could
improve the inﬂammatory and oxidative stress of CP rats. Other
researches also found that the antioxidant effect of DMF could
protect the islet from the effect of L-arginine induced inﬂam-
matory response [19,20]. It also indicated that DMF could reduce
the levels of MPO and MDA to inhibit the inﬂammatory and
oxidative stress of CP rats and thus protect the islet.
In conclusion, long-term DMF treatment can effectively
improve the histopathological changes, biochemical abnormal-
ities and beta cell function in rats with CP. In the further studies,
it is necessary to conﬁrm the efﬁcacy and side effects of DMF in
the clinical practice.
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